Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
The facility will manufacture tablets, capsules, and injections for the oncology segment
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
To accelerate the development of next-generation radioconjugates to treat cancer
Mungara has over 25+ years of experience in the supply chain domain
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Subscribe To Our Newsletter & Stay Updated